LogicBio Therapeutics (NASDAQ:LOGC) posted its quarterly earnings results on Tuesday. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.04), Fidelity Earnings reports.
Shares of LOGC stock traded down $1.49 during mid-day trading on Wednesday, reaching $8.01. The stock had a trading volume of 647 shares, compared to its average volume of 21,328. The company has a 50-day moving average price of $12.11. LogicBio Therapeutics has a 52-week low of $6.70 and a 52-week high of $20.07. The company has a market capitalization of $221.57 million and a price-to-earnings ratio of -2.63.
LOGC has been the subject of several recent research reports. Chardan Capital reissued a “buy” rating on shares of LogicBio Therapeutics in a research note on Monday, July 29th. Roth Capital initiated coverage on shares of LogicBio Therapeutics in a research note on Wednesday, May 1st. They issued a “buy” rating and a $26.00 price target for the company. ValuEngine raised shares of LogicBio Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Finally, Zacks Investment Research upgraded shares of LogicBio Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $24.00.
About LogicBio Therapeutics
LogicBio Therapeutics, Inc, a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect.
Further Reading: How is a Moving Average Calculated?
Receive News & Ratings for LogicBio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LogicBio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.